6. Quality Performance Indicator for Clinical Trial Access
|QPI Title:||All patients should be considered for participation in available clinical trials, wherever eligible.|
|Description:||Proportion of patients with [insert tumour type] cancer who are consented* for a clinical trial.|
|Rationale and Evidence:||Clinical trials are necessary to demonstrate the efficacy of new therapies and other interventions. Furthermore evidence suggests improved patient outcomes from participation in clinical trials  . Clinicians are therefore encouraged to enter patients into well-designed trials and to collect longer-term follow-up data. High accrual activity into clinical trials is used as a goal of an exemplary clinical research site.|
Number of patients with [insert tumour type] cancer consented for a clinical trial.
All patients with [insert tumour type] cancer.
|Target:||15% The target level has been agreed based on National Cancer Research Institute ( NCRI) data (see appendix 5).|
*consented is defined as patients who have given consent to participate in a clinical trial subject to study specific screening for eligibility.
Updated to measure patients consented rather than enrolled
Combined target of 15% (for all types of trials)
Email: Chris Booth, email@example.com
Phone: 0300 244 4000 – Central Enquiry Unit
The Scottish Government
St Andrew's House